Mini review: The FDA-approved prescription drugs that induce ovulation in women with ovulatory problems

被引:5
|
作者
Sun, Chunlei [1 ]
Rong, Xi [2 ]
Cai, Yongqin [3 ]
Qiu, Song [4 ]
Farzaneh, Maryam [5 ]
机构
[1] Yidu Cent Hosp Weifang, Dept Pediat, Weifang, Peoples R China
[2] Yidu Cent Hosp Weifang, Dept Pharm, Weifang, Peoples R China
[3] Yidu Cent Hosp Weifang, Dept Gynaecol, Weifang, Peoples R China
[4] Weifang Peoples Hosp, Imaging Dept Brain Hosp, Weifang 261021, Peoples R China
[5] Ahvaz Jundishapur Univ Med Sci, Physiol Res Ctr, Ahvaz, Iran
关键词
FDA-approved drugs; in vitro fertilization; infertility; ovulation; polycystic ovary syndrome; FOLLICLE-STIMULATING-HORMONE; POLYCYSTIC-OVARY-SYNDROME; CLOMIPHENE CITRATE; CORIFOLLITROPIN ALPHA; BROMOCRIPTINE TREATMENT; FEMALE INFERTILITY; PREGNANCY RATE; LETROZOLE; GONADOTROPINS; METFORMIN;
D O I
10.1002/ddr.21687
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Infertility is defined as not being able to become pregnant after 12 months or more of unprotected sexual intercourse. Female infertility as a serious health issue can result from ovulation disorders, menstrual cycle problems, structural problems, and environmental factors. Ovulation occurs once a month between the time of menarche and menopause. The release of a mature egg from the ovary is controlled with the hypothalamic-pituitary-ovarian axis. Several hormones such as gonadotropin-releasing hormone (GnRH), FSH (follicle-stimulating hormone), LH (luteinizing hormone), estrogen, and progesterone play fundamental roles in the ovulation process. Both FSH and LH are the main treatment for women with ovulation disorders. Depending on the reasons for infertility, several different types of treatment are available for infertile women. Fertility drugs as an important part of treatment work like the natural hormones to treat infertility. Several fertility drugs can regulate ovulation and the release of an egg from the ovary in women with polycystic ovary syndrome (PCOS) or undergoing in vitro fertilization (IVF) treatment. This mini-review is about the FDA-approved prescription drugs that induce ovulation in women with ovulatory problems.
引用
收藏
页码:815 / 822
页数:8
相关论文
共 50 条
  • [21] An analysis of FDA-approved drugs for neurological disorders
    Kinch, Michael S.
    DRUG DISCOVERY TODAY, 2015, 20 (09) : 1040 - 1043
  • [22] A systematic analysis of FDA-approved anticancer drugs
    Sun, Jingchun
    Wei, Qiang
    Zhou, Yubo
    Wang, Jingqi
    Liu, Qi
    Xu, Hua
    BMC SYSTEMS BIOLOGY, 2017, 11 : 27 - 43
  • [24] Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling
    Bansri Desai
    Kyungwan Hong
    John H. Powers
    Peter Doshi
    Journal of General Internal Medicine, 2020, 35 : 377 - 379
  • [25] Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling
    Desai, Bansri
    Hong, Kyungwan
    Powers, John H.
    Doshi, Peter
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (01) : 377 - 379
  • [26] FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years
    Nair, Aathira Sujathan
    Singh, Ashutosh Kumar
    Kumar, Astik
    Kumar, Sunil
    Sukumaran, Sunitha
    Koyiparambath, Vishal Payyalot
    Pappachen, Leena K.
    Rangarajan, T. M.
    Kim, Hoon
    Mathew, Bijo
    PROCESSES, 2022, 10 (10)
  • [27] Review on fluorinated nucleoside/non-nucleoside FDA-approved antiviral drugs
    Ismail, Magda M. F.
    Ayoup, Mohammed Salah
    RSC ADVANCES, 2022, 12 (48) : 31032 - 31045
  • [28] FDA-approved drugs containing dimethylamine pharmacophore: a review of the last 50 years
    Bindra, Sandeep
    Bose, Kuntal
    Thekkantavida, Amrutha Chandran
    Parambi, Della Grace Thomas
    Alsahli, Tariq G.
    Pant, Manu
    Pappachen, Leena K.
    Kim, Hoon
    Mathew, Bijo
    RSC ADVANCES, 2024, 14 (38) : 27657 - 27696
  • [29] Pharmacogenomic characterization of US FDA-approved cytotoxic drugs
    Peters, Eric J.
    Motsinger-Reif, Alison
    Havener, Tammy M.
    Everitt, Lorraine
    Hardison, Nicholas E.
    Watson, Venita G.
    Wagner, Michael
    Richards, Kristy L.
    Province, Mike A.
    McLeod, Howard L.
    PHARMACOGENOMICS, 2011, 12 (10) : 1407 - 1415
  • [30] Repurposing FDA-approved drugs as potential PARP inhibitors
    Eznarriaga, Maria
    Rahman, Taufiq
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (11) : 2516 - 2516